^
    Back
    Association details:
    Biomarker:CD74-ROS1 rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:unecritinib (TQ-B3101) (ALK inhibitor, ROS1 inhibitor, c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Signal Transduct Target Ther
    Title:

    Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

    Published date:
    06/30/2023
    Excerpt:
    Twenty-seven patients who had CD74-ROS1 rearrangements exhibited a notable response to unecritinib therapy, with CR in 1 patient and PR in 23 patients, and an ORR of 88.9% (95% CI 70.8%, 97.7%).
    DOI:
    https://doi.org/10.1038/s41392-023-01454-z